Abstract
Acid-related diseases (ARD) including gatroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) are treated by acid suppression drugs, especially proton pump inhibitor (PPI). Use of PPI as a first line therapy for ARD is recommended in various guidelines. Recently, vonoprazan, a new class of acid secretion inhibitor called potassium-competitive acid blocker (P-CAB) developed in Japan for the treatment of ARD. The drug is covered by the Japanese medical insurance for the treatment of ARD, and it is reported that Helicobacter pylori (HP) eradication rate with it is more than 90%.
| Original language | English |
|---|---|
| Pages (from-to) | 1136-1146 |
| Number of pages | 11 |
| Journal | Nippon rinsho. Japanese journal of clinical medicine |
| Volume | 73 |
| Issue number | 7 |
| Publication status | Published - 2015 Jul 1 |